Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Nursing Home & Skilled Nursing Facility Experts

Analysis of: Note to Medicaid Patients: The Doctor Won't See You (online.wsj.com)
Reimbursement has continued to either remain flat or decline in the setting of rising office overhead costs.   Medicaid, which covers those that are the poorest with the least access to care provides even worse reimbursement. In the setting of being able to run a practice effectively, Medicaid...
Analysis of: HMOs to start ad blitz against Medicare cuts (news.yahoo.com)
First they want to keep cutting physician reimbursements like medicare, but when they realize medicare cuts may affect their ability to provide care for medicare patients, now they want raises? Certainly not a dime of what they want from the government will be put back in the pockets of physicians. ...
Analysis of: Curbing chronic diseases new issue in health-care politics (www.kansascity.com)
Chronic disease, by nature requires continuous management.    With disease such as diabetes, COPD, hypertension (and it's systemic manifestation), congestive heart failure and heart disease, many patients require round the clock medications, physician or nurse practioner management, and...
Glen McDaniel, MS, MBA, President and Chief Executive Officer
Glen McDaniel, MS, MBA, President and Chief Executive Officer
GM Global
Analysis of: An Innovation in Health Care Opens at CVS/Pharmacy Stores in Knoxville and Chattanooga (money.cnn.com)
Mini clinics will continue to operate in retail establishments for the forseeable future.  They have raised several concerns, so the company that addresses these concerns while providing the convenience will be rewarded with above average market share.
Analysis of: Blue Cross cuts causing pain (www.latimes.com)
There is a simple rule of economics. If product A costs $10 to make and sells for $15, the profit is $5. If you outsource your manufacturing to China and get the cost to $5, you make $10. The goal of any for profit business is to make money, and the only way to do that is to cut costs or increase revenue....
Analysis of: Radiation Oncology - Nucletron Introduces New MicroSelectron™ Digital Afterloader To Efficiently Meet Patient Needs And Future Demands (www.medicalnewstoday.com)
Nucletron, arguably the leader in HDR afterloaders now has a 3rd generation machine - the Digital Microselectron.   This unit differs slightly from the very popular 2nd generation  (v2) Microselectron in that it allows scalability in the number of channels availble for source delivery...
Analysis of: An Innovation in Health Care Opens at CVS/Pharmacy Stores in Knoxville and Chattanooga (money.cnn.com)
Several retail pharmacies and walmart are opening 'urgent care' centers to diagnose and treat patient for low cost, and a short wait. The intention is good, and will likely keep some people from going to the ER.  However, several problems of concern. In the end it's probably a plus for the uninsured...
Analysis of: Wyeth Receives Approvable Letter from FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated with Menopause (www.pipelinereview.com)
Pristiq has received a letter of approval, but still must undergo some additional safety checks.   The FDA wants evidence that there is not significant adverse cardiac or hepatic events with this drug, and is asking for a randomized trial to prove it. Since the trial must have at least a year of...
Analysis of: FDA Oncologic Drugs Advisory Committee Recommends that FDA Wait for Overall Survival Results from Satraplatin Phase 3 Trial (www.pipelinereview.com)
Satraplatin, and oral platinum based chemotherapy is under investigation in several applications including hormone refractory prostate cancer, and lung cancer. The SPARC trial (Satraplatin and Prednisone Against Refractory Cancer), evaluating Satraplatin plus prednisone vs. placebo has randomized...
Analysis of: Arius begins toxicology program for lead anti-cancer antibody in preparation for first human studies (www.pipelinereview.com)
Antibodies against CD44 are an interesting and novel idea in treating cancers.   Arius has theorized that cancer stem cells, which can survive cytotoxic treatment can be identified and targed for cell death via a CD44 antibody.   Preclinical models have demonstrated potent inhibition...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next71 to 80 of 155

Analytics


Generated at 2009-01-07T19:00:58.307